We focus on developing novel, transformative cancer therapeutics.
Our vision is to deliver innovative medicines to patients while fostering synergistic long-term collaborations with leading biopharmaceutical companies and by partnering with leading medical centers on the development of our therapeutics.
Biond Biologics is collaborating with Sanofi for the development and commercialization of BND-22.BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. ILT2, is an inhibitory receptor expressed on both innate and adaptive immune cells. Biond is leading the first-in-human, phase 1a study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics. Sanofi will assume clinical development and commercialization responsibilities thereafter.